These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20387361)

  • 1. Repaglinide induced acute hepototoxicity.
    Jaiswal S; Mehta R; Musuku M; Tran L; McNamee W
    JNMA J Nepal Med Assoc; 2009; 48(174):162-4. PubMed ID: 20387361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute hepatotoxicity caused by repaglinide.
    Nan DN; Hernández JL; Fernández-Ayala M; Carrascosa M
    Ann Intern Med; 2004 Nov; 141(10):823. PubMed ID: 15545689
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
    Owens D
    J Assoc Physicians India; 2001 Jan; 49 Spec No():54-61. PubMed ID: 11235607
    [No Abstract]   [Full Text] [Related]  

  • 4. Cholestatic hepatitis associated with repaglinide.
    López-García F; Borrás J; Verdú C; Salazar VR; Ruiz JA; Sales J; Lucena MI; Andrade RJ
    Diabetes Care; 2005 Mar; 28(3):752-3. PubMed ID: 15735221
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].
    Landgraf R
    MMW Fortschr Med; 2000 Jul; 142(28-29):29-30. PubMed ID: 10959157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed hypoglycemia induced by repaglinide in a frail elderly adult with diabetes mellitus.
    Mennecart M; Mondon K; Malherbe C; Constans T
    J Am Geriatr Soc; 2014 Dec; 62(12):2460-2. PubMed ID: 25516054
    [No Abstract]   [Full Text] [Related]  

  • 7. Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia.
    Ambavane V; Patil R; Ainapure SS
    J Postgrad Med; 2002; 48(3):246-8. PubMed ID: 12432213
    [No Abstract]   [Full Text] [Related]  

  • 8. Severe hypoglycemia from clarithromycin-repaglinide drug interaction.
    Khamaisi M; Leitersdorf E
    Pharmacotherapy; 2008 May; 28(5):682-4. PubMed ID: 18447665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study.
    Jovanovic L; Dailey G; Huang WC; Strange P; Goldstein BJ
    J Clin Pharmacol; 2000 Jan; 40(1):49-57. PubMed ID: 10631622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical and clinical studies on safety and tolerability of repaglinide.
    Schatz H
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S144-8. PubMed ID: 10522841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoglycemia probably due to accidental intake of repaglinide.
    Lee IT; Sheu WH; Lin SY
    Chang Gung Med J; 2002 Nov; 25(11):783-6. PubMed ID: 12553369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe hypoglycaemia from repaglinide-brotizolam drug interaction: a case report and literature review.
    Khamaisi M
    Diabet Med; 2012 Sep; 29(9):1214-5. PubMed ID: 22414218
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function.
    Hasslacher C;
    Diabetes Care; 2003 Mar; 26(3):886-91. PubMed ID: 12610054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repaglinide and diabetes: new preparation. No better than glucose-lowering sulphonamides.
    Prescrire Int; 2001 Feb; 10(51):9-11. PubMed ID: 11503861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypersensitivity to repaglinide.
    Rojas P; Sánchez L; Santos A; Góõmez MP; Blanco H; Laguna JJ
    J Investig Allergol Clin Immunol; 2011; 21(3):245-7. PubMed ID: 21548456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
    Li C; Xia J; Zhang G; Wang S; Wang L
    Acta Diabetol; 2009 Dec; 46(4):325-33. PubMed ID: 19183841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus.
    Guay DR
    Pharmacotherapy; 1998; 18(6):1195-204. PubMed ID: 9855316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient.
    Roustit M; Blondel E; Villier C; Fonrose X; Mallaret MP
    Ann Pharmacother; 2010 Apr; 44(4):764-7. PubMed ID: 20197475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy in type 2 diabetes: the role of repaglinide.
    Moses R
    J Assoc Physicians India; 2001 Jan; 49 Spec No():62-8. PubMed ID: 11235608
    [No Abstract]   [Full Text] [Related]  

  • 20. Repaglinide dose response? A clinician's viewpoint.
    Strange P; Goldberg RB
    Diabetes Technol Ther; 2000; 2(1):119-21. PubMed ID: 11467310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.